恩替卡韦联合强肝片治疗乙肝肝硬化的临床效果观察

Clinical effect observation of Entecavir combined with Qianggan tablets in treating Hepatitis B liver cirrhosis

目的:探讨恩替卡韦联合强肝片治疗乙肝肝硬化的临床效果。方法:研究我院2014年6月—2015年12月收治的80例乙肝肝硬化患者,分为对照组和观察组各40例,其中对照组运用强肝片治疗,观察组运用恩替卡韦联合强肝片治疗,分析两组治疗效果差异。结果:在治疗总有效率上,观察组为95%,对照组为82.5%,两组差异具有统计学意义,P<0.05;在治疗后肝功能、Child-Pugh评分、HBV-DNA和纤维环指标上,观察组改善幅度要高于对照组,两组差异具有统计学意义,P<0.05。结论:恩替卡韦联合强肝片治疗乙肝肝硬化可以有效提升治疗疗效,改善相关机体功能指标,患者满意度高,值得临床广泛推广。

Objective: To explore the clinical effect of Entecavir combined with Qianggan tablets in treating Hepatitis B livercirrhosis. Methods: 80 patients with hepatitis B liver cirrhosis, admitted to and treated in our hospital from June 2014 to December 2015,were divided into the control group and the observation group, with 40 cases in each group, the control group received Qianggan tabletswhile the observation group received Entecavir combined with Qianggan tablets, the difference of therapeutic effects of two groups wasanalyzed. Results: As for the total effective rate, the observation group was 95% while that of the control group was 82.5%, the differencewas statistically significant, P<0.05; after treatment, the improvement of the liver function, Child-Pugh score, HBV-DNA and annulusindex of the observation group was higher than that of the control group, the difference was statistically significant, P<0.05. Conclusion:Entecavir combined with Qianggan tablets could enhance treatment efficacy effectively in treating Hepatitis B liver cirrhosis, it couldimprove related body function indicators and the patients satisfaction, and was worthy of clinical promotion.